# Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

> **NCT04850157** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

## Interventions

- **DRUG:** Tislelizumab
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT04850157
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-20
- **Primary completion:** 2022-04-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850157, "Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04850157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*